Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Foundation models for electrocardiogram interpretation: clinical implications

Nolin-Lapalme A, Sowa A, Delfrate J, Tastet O, Corbin D, Kulbay M, Ozdemir D, Noël MJ, Marois-Blanchet FC, Harvey F, Sharma S, Ansari M, Chiu[...]

Temporal trends in the clinical utilization of cardiac imaging tests: 2008-2024

Rozanski A, Gransar H, Miller R, Slomka P, Han D, Hayes S, Friedman J, Berman D. Temporal trends in the clinical utilization of cardiac imaging[...]

Improved Assessment of Coronary Artery Disease in Obese Subjects with Flurpiridaz-18F PET Myocardial Perfusion Imaging: A Prespecified Subgroup Analysis of the AURORA Phase 3 Study

Patel KK, Maddahi J, Agostini D, Bax JJ, Beanlands RSB, Berman D, Dorbala S, Heller GV, Knuuti JM, Pelletier-Galarneau M, Tamaki N, Thompson D, Somer[...]